BCPEM
ALXN

Bain Capital Public Equity Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bain Capital Public Equity Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-70,753
Closed -$8.78M – 84
2018
Q2 		$8.78M Buy
70,753
+13,768
+24% +$1.61M 0.59% 33
2018
Q1 		$6.35M Buy
+56,985
New +$6.81M 0.46% 43

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bain Capital Public Equity Management's ALXN Position: Q3 2018 in Review

Bain Capital Public Equity Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 70,753 shares — an estimated $8.78M sold.

Bain Capital Public Equity Management first reported a position in ALXN in Q1 2018 and held it in 2 quarters. The position peaked at $8.78M in Q2 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Bain Capital Public Equity Management reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 70,753 Alexion Pharmaceuticals shares in Q3 2018, an estimated $8.78M.
  • Bain Capital Public Equity Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Bain Capital Public Equity Management's Alexion Pharmaceuticals position peaked at $8.78M in Q2 2018.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.